Key Trends and Insights into the Non-Alcoholic Steatohepatitis Treatment Market: Growth Rate and Opportunities to 2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the non-alcoholic steatohepatitis treatment market grown over the years?
The market size of treatment for non-alcoholic steatohepatitis has seen considerable growth in the past few years, escalating from $2.6 billion in 2024 to $3.6 billion by 2025, with a compound annual growth rate (CAGR) of 38.5%. The exponential growth witnessed in this historical period is due to factors such as increased NASH prevalence, enhanced awareness and diagnosis, change in lifestyle leading to obesity, advancements in clinical research, improvements in healthcare infrastructure and access, supportive regulations, and numerous clinical trials.
What Is the forecasted market size and growth rate for the non-alcoholic steatohepatitis treatment market?
The market size for non-alcoholic steatohepatitis treatment is projected to experience significant growth in the coming years. The growth is predicted to reach $13.83 billion by 2029, growing at a compound annual growth rate (CAGR) of 40.0%. Several factors contribute to this anticipated growth during the forecast period. These include the flourishing advancements in drug development, greater public knowledge of the disease, an increasing rate of prevalence and risk factors, and a shift in focus towards personalized medicine. The upcoming trend forecasts highlight a patient-centric approach, further technological advancements, precision-targeted therapies, an evolving regulatory landscape, and breakthroughs in research.
Get your non-alcoholic steatohepatitis treatment market report here!
What are the major factors driving growth in the non-alcoholic steatohepatitis treatment market?
The non-alcoholic steatohepatitis treatment market continues to grow, driven by an increasing incidence of insulin resistance. Insulin resistance, a condition wherein liver, fat, and muscle cells do not sufficiently react to insulin and fail to absorb glucose from the bloodstream efficiently, leads to elevated blood sugar. This condition can be attributed to unhealthy lifestyles, excessive intake of sugar, and genetic disposition. The need for tackling insulin resistance has grown due to the rising cases of diabetes and other liver-related illnesses, requiring non-alcoholic steatohepatitis treatment. As per a report from the International Diabetes Federation, a Belgium-based global diabetes community, in January 2022, diabetes affected 537 million individuals aged between 20-79 years, representing one in every ten people worldwide. This figure is projected to rise to 643 million by 2030 and ballooning further to 783 million by 2045. Additionally, the American Cancer Society, a US-based non-profit cancer advocacy organization, predict an increase in the new cases of liver cancer to 41,630 in 2024 from 41,210 in 2023, in their January 2024 statement. Consequently, the increased occurrence of insulin resistance brought about by numerous diseases linked to the liver and diabetes will fuel the growth of the non-alcoholic steatohepatitis treatment market.
What key areas define the segmentation of the global non-alcoholic steatohepatitis treatment Market?
The non-alcoholic steatohepatitis treatment market covered in this report is segmented –
1) By Drug Type: Vitamin E And Pioglitazone, Ocaliva, Elafibranor, Selonsertib And cenicriviroc, Obeticholic Acid, Other Drugs Types
2) By Test Type: Blood Tests, Liver Biopsy, Imaging Procedures
3) By End User: Hospital Pharmacies, Retail And Specialty Pharmacies, Other End Users
Subsegments:
1) By Vitamin E And Pioglitazone: Vitamin E Supplements, Pioglitazone-Based Formulations.
2) By Ocaliva: Ocaliva (Obeticholic Acid) For NASH
3) By Elafibranor: Elafibranor-Based Treatments
4) By Selonsertib And Cenicriviroc: Selonsertib Formulations, Cenicriviroc Formulations
5) By Obeticholic Acid: Other Formulations Of Obeticholic Acid
6) By Other Drug Types: Novel Agents In Clinical Trials, Combination Therapies
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8595&type=smp
What are the top market players propelling the growth of the non-alcoholic steatohepatitis treatment industry?
Major companies operating in the non-alcoholic steatohepatitis treatment market are AstraZeneca PLC, Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Novo Nordisk A/S, Immuron Ltd., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG
What are the key trends shaping the future of the non-alcoholic steatohepatitis treatment market?
The evolution of the drug for non-alcoholic steatohepatitis (NASH) is a significant trend gaining traction in the market for NASH treatment. Several companies are dedicating resources to develop cutting-edge medications for liver diseases that minimize the side effects. For example, Pfizer Inc., a well-known pharmaceutical and biotechnology firm from the United States, received a fast-track designation from the U.S. Food and Drug Administration (FDA) in May 2022, to expedite the development of the NASH drug, namely ervogastat and clesacostat. This fast-track procedure is aimed at Pfizer’s proposed combinatorial therapy for treating NASH with liver fibrosis, referred to as ervogastat (PF-06865571, a diacylglycerol O-acyltransferase 2 inhibitor, or DGAT2i) and clesacostat (PF-05221304, an acetyl-CoA carboxylase inhibitor, or ACCi).
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8595
What regions are dominating the non-alcoholic steatohepatitis treatment market growth?
North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2024. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Browse Through More Similar Reports By The Business Research Company:
Protein Supplements Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/protein-supplements-global-market-report
Nutritional Analysis Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/nutritional-analysis-global-market-report
Probiotics Dietary Supplements Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
